New NEA Fund Could Bring $1 Billion To Health Care
Following two years of strong exits from biopharma and medtech investment, New Enterprise Associates raised over $3.1 billion for its 15th fund raising. The new pool of capital consists of $2.8 billion for a traditional venture fund – the fourth consecutive fund to top $2.5 billion – and a $350 million “Opportunity Fund” that will be co-invested with the new and prior fund in late-stage growth equity deals.
You may also be interested in...
Newly Public Medtechs Gain In Share Price, Market Cap
The device IPO class of 2014 gained on share price, with several outperforming by more than 100%, and market caps for larger companies have grown at a rapid pace.
Timing, Returns Record Right For Vivo Capital Fundraising
Once a lesser known firm in US life sciences investing, Vivo Capital has emerged as a global leader in biopharmaceutical and medtech start-ups, raising a $750 million fund that will be invested in the US, Europe, and China.
Abbott, NEA Show Medtech Deals Still Have Some Pop
With a paucity of VC firms willing to invest in medtech companies, strategic players are being called upon to assume larger, more active roles in the process of starting and funding the start-ups that they may someday acquire. Last month, Abbott made a forceful move into the electrophysiology space with a trio of deals involving companies backed by New Enterprise Associates.